Indian Biotechnology Sector§ The Biotechnology industry in ₰ In Asia Pacific market, India India to reach $11.6 billion by occupies 28.66% market share. 2017-Global Industry Analysis. ₰ India is in 12th rank in the§ The opportunities for investors in world in biotechnology and Biotech industry are manifold. 3rd largest in Asia-Pacific after§ In 2010-11 the Indian Biotech Japan and Korea. industry registered 21.5% growth, ₰ The Sector employees touching $4 billion mark clocking approximately 20,000 Rs 18,399.34 Cr. scientists and over 352§ The Biopharma segment continues companies drive it towards to dominate biotech industry with further growth. 61.77% share in the overall ₰ Karnataka is the Biotech revenue. Capital of India
Karnataka-India’s Biotech Hub₴ The Biotech capital of India. • Extensive Intellectual Capital₴ 60% of biotech companies are – Sector focused SEZs-Mysore, having base in Bangalore. Mangalore, Hubli-Dharward,₴ 50% of the total revenues in Belgaum, Shimoga, national biotechnology sector. Gulbarga,Kolar & Mandya.₴ Growth in industrial output of – 86 acre Bitochnology park- Karnataka’s biotech companies “Bangalore Helix” with 52 acre CAGR 11% per annum. Alexandria Knowledge Park in₴ Extensive Intellectual Capital Bangalore. – 12 Biotechnology finishing • Pro Industry policy-State Millennium schools under millennium Biotech Policy II 2010, State biotech policy II Industrial Policy 2009-14 – 103 R&D Centers – K-Bio Venture capital fund of US$ 10.4 million with 26% stake holding by GoK
Divisions The Indian Biotechnology sector can be divided into the segments of biopharmaceuticals, bioservices, bioagriculture, bioindustrial and bioinformatics. Nearly 40 percent of the biotech companies operate in the biopharma sector, followed by the bioservices (21 percent), bioagri (19 percent), bioinformatics (14 percent) and lastly the bioindustrial sector (5 percent).
Biopharmaceuticals Bioservices• This constitutes the largest • The Bioservices market is segment of the Indian biotech the second largest sector of industry both in terms of the Indian Biotechnology domestic and export revenues. Industry.• About 70 percent of the domestic biotech industry comprises of the • The market’s growth can be Biopharma sector. attributed to the fact that• Of the total 325biotechnology India has become a popular companies in India, more than 40 destination for clinical trial, percent are in the biopharma contract research and sector. manufacturing activities.• Vaccines, therapeutics and diagnostics fall into this category.
Agricultural Bioinformatics / BioIT Biotechnology• This segment can be segmented • This sector deals with the into Hybrid seeds and transgenic creation and maintenance of crops, Biopesticides and extensive electronic databases Biofertilizers. on various biological systems and is probably the smallest part of the current domestic• Genetically modified cotton or biotechnology industry. commonly known as Bt cotton • However, India is known for constitute approximately 77 its strong IT base and it is due percent of the revenue of this to this that India is sure to sector whereas Biopesticides and become a leading destination Biofertilizers together account for work in the bioinformatics only for 23 percent of the arena. revenues by agricultural biotechnology.
Bioindustrial• This industry predominantly consists of enzyme manufacturing and marketing companies.• These enzymes are used in industries such as detergents, textiles, food, leather, paper and pharmaceuticals. This generates 6 percent of the revenues of the biotechnology industry.
List of Top Biotech 20 Companies Serum Institute of India Biocon Panacea Biotec Rasi Seeds Nuziveedu Seeds Novo Nordisk India Venkateshwara Hatcheries Indian Immunologicals Mahyco Monsanto Biotech GlaxoSmithKline Pharma Aventis Pharma Shantha Biotechnics Eli Lilly and Company(India) Mahyco Seeds Bharat Serums and Vaccines Novozymes South Asia Invert India Bharat Biotech International Ankur Seeds Advanced Enzyme Technologies
Serum Institute of Biocon Panacea Biotec India Vaccine King Collective Expertise Product Innovation With a record sales of Rs 950.95 Biocons integrated business crore in 2010-11, approach coupled with its Panacea Biotec has added new drugs to collective expertise has its product basket like Siropan,Serum Institute of India continues to enabled it to establish a be a leader in the vaccines Lower A, Myelogen Forte, Inrica, significant presence in the TOFF Expectorant, Toff DC, market. global Business: Manufacturing and Upright SP and Trepro. biopharmaceutical market. Business: Manufacturer of marketing of vaccines Business: Biopharmaceuticals pharmaceuticals and and immuno-biologicals and industrial enzymes biopharmaceuticals CEO: Dr C S Poonawalla (CMD) CEO: Kiran Mazumdar Shaw CEO: Soshil Kumar Jain (MD) Biotech Revenue: Rs 950.95 crore Biotech Revenue: Rs 823 crore Biotech Revenue: Rs 600 crore Start-up Year: 1966 Start-up Year: 1978 Start-up Year: 1984 Address: 212/2, Hadapsar, Off Soli Address: 20th KM Hosur Road, Address: B-1 Extn/G-3, Mohan Co- Poonawalla Road, Electronic City, Bangalore – operative Industrial Estate, Mathura Pune- 411 028 560100 Road, New Delhi – 110 044
Nuziveedu Seeds Rasi Seeds Novo Nordisk India Bt Cotton Maker Transgene Developer Insulin Leader Novo Nordisk India enjoys a lionsRasi Seeds accounted for 35 Nuziveedu Seeds is working on share in the Indian insulin percent of the total Bt its own indigenous transgene market. cotton seeds sold in India to combat bollworms and in the year 2011. these technologies are Business: Producing and expected to be Novo Nordisk India marketing commercialized soon. CEO: Melvin Oscar DSouza (MD)agri-biotechnology products Business: Manufacturer of hybrid Biotech Revenue: Rs 222 crore CEO: M Ramasami (MD) cotton seeds Business: Diabetes care products,Biotech Revenue: Rs 333.33 CEO: M Prabhakar Rao human growth hormone and crore Biotech Revenue: Rs 226.42 crore haemostasis management. Start-up Year: 1973 Start-up Year: 1973 Start-up Year: 1990Address: 273, Kamarajanar Address: 7C, Surya Towers, 105 Road, Attur, Salem - 636 SP Road, Secunderabad – Address: 8th Floor, Raheja Towers, 102, Tamil Nadu 500 003 East Wing, 26/27, MG Road, Bangalore- 560 001
Venkateshwara Indian Mahyco Monsanto Hatcheries Immunologicals Biotech Poultry Passion Animal Health Specialist The Technologist Mahyco Monsanto Biotech (India), a Venkateshwara Hatcheries Indian Immunologicals Ltd (IIL) 50:50 joint venture with Mahyco dominates the Indian poultry has bagged the distinction of and Monsanto Holdings Pvt Ltd vaccines market being the largest exporter of (MHPL), was created to bring the with a share of over 60 percent. veterinary biological in Asia. benefits of Bollgard cotton Venkateshwara Hatcheries Indian Immunologicals Ltd (IIL) technology to farmers in India. Business: Engaged in R&D, Business: Manufacturer of animal Mahyco Monsanto Biotech (India) production and export of and human biological Business: Marketing of Bt technology vaccines and diagnostics kits CEO: KV Balasubramaniam in India CEO: Anuradha Desai Biotech Revenue: Rs 157.90 crore CEO: Dr MK Sharma (MD) (Chairperson) Start-up Year: 1983 Biotech Revenue: Rs 150.30 crore Biotech Revenue: Rs 190.50 crore Address: Road No.44, Jubilee Start-up Year: 1998 Start-up Year: 1971 Hills, Hyderabad - 500 033 Address: Ahura Centre, 5th Floor, 96,Address: Venkateshwara House, SN Mahakali Caves Road, Andheri 114/A/2, (East),Pune - Sinhgad Road,Pune - 411030 Mumbai - 400 093
GlaxoSmithKline Shantha Pharma Aventis Pharma Biotechnics Novel Concepts Anti-rabies Vaccine Leader The Trend SetterWith growing competition from the local low-priced products, GSK As the first Indian company to launch has initiated novel concepts to an r-DNA vaccine in 1997, bring awareness on the use of Aventis Pharma leads the anti-rabies Shantha heralded a new beginning vaccines in the country. vaccine market in India, having for biotechnology in India.GlaxoSmithkline Pharmaceuticals a market share of 60 percent. Shantha Biotechnics Business: Engaged in the sale of Aventis Pharma Business: Research, development, Business: Marketing of manufacture and marketing of vaccines biotechnology products biotechnology-based human healthCEO: Dr Hasit B Joshipura (MD) care products Biotech Revenue: Rs 120 crore CEO: Dr Shailesh Ayyangar (MD) CEO: KI Varaprasad Reddy Start-up Year: 2001 Biotech Revenue: Rs 119.65 crore Biotech Revenue: Rs 115 crore Address: GSK House, Dr Annie Address: Aventis House, 54/A, Sir Start-up Year: 1993 Besant Road, Worli, Mumbai - Mathuradas Vasanji Road, 400030 Andheri (East), Mumbai - 400 Address: Serene Chambers, 3rd Floor, 093 Banjara Hills, Road No. 7, Hyderabad - 500 034
Eli Lilly and Bharat Serums and Company(India) Mahyco Seeds Vaccines TB Fighter Bt Cotton Pioneer Recombinant Therapeutics Player Bharat Serums and Vaccines has Established in 1964, Mahyco is a been focusing on developing pioneer and leader in the Indian new generation recombinantEli Lilly India has committed $50 therapeutics that replace the million to fight Multi-Drug seed industry. traditional plasma products Resistant Tuberculosis (MDR- Maharashtra Hybrid Seed Company TB). Ltd Bharat Serums and Vaccines Eli Lilly & Company (India) Business: Diagnostics solutions for Business: Manufacturing and GM crop testing marketing of biological Business: Marketing of products pharmaceutical products CEO: BR Barwale (Chairman) CEO: Bharat Daftary (CMD) CEO: Sandeep Gupta (MD) Biotech Revenue: Rs 110.69 crore Biotech Revenue: Rs 108.49 crore Biotech Revenue: Rs 112 crore Start-up Year: 1964 Start-up Year: 1971 Start-up Year: 1993 Address: PO Box 76, Jalna - Aurangabad Road, Dawalwadi, Address: 16th Floor, HoechstAddress: Plot No. 92, Sector 32, House, Nariman Point, Mumbai Institutional Area, Gurgaon - Dist.- Jalna, - 400 021 122 001 Maharashtra – 431203
Novozymes South Bharat Biotech Asia Invert India International Enzymatic Endeavors The Veterinarian Healthcare Specialist Intervet India is one of the largest MNCs in India dedicated to animal health. It offers a range of products consisting of biological, therapeutics and productive hormones. Bharat Biotech was established in 1996Novozymes produces and sells more Intervet India with the objective of than 600 enzyme products in manufacturing unique vaccines 130 different countries, the Business: R&D and manufacturing and biotherapeutics. largest geographical markets of veterinary biological Bharat Biotech International being Europe, North America CEO: Dr Lino Componovo (MD) and Asia. Business: Manufacturer of human Biotech Revenue: Rs 80.58 crore vaccines and biopharmaceuticals Novozymes South Asia CEO: Dr Krishna M Ella Business: Industrial enzymes Start-up Year: 1997 Biotech Revenue: Rs 70.27 crore CEO: GS Krishnan Address: Intervet House, 33, Pune- Start-up Year: 1996 Biotech Revenue: Rs 100 crore Nagar Road, (Behind Eden New initiatives: Manufacture of human Start-up Year: 2000 Gardens), Pune - 411 014 rabies vaccines, formulation ofAddress: #16, 7th Floor, Innovator, various vaccines and International Technology Park, biopharmaceuticals. Address: Road No. 65 Jubilee Hills, Whitefield Road, Bangalore - Hyderabad 560 066
Advanced Enzyme Ankur Seeds Technologies Agribiotech Player The Catalyst Advanced Enzyme Technologies Ankur Seeds boasts of having produces enzymes and probiotics over 115 hybrids in various worth over $20 million annually crops. It also has a large and it is the largest manufacturer collection of proprietary of serratiopeptidase. germplasm with novel traits Advanced Enzyme Technologies of all crops. Business: R&D, manufacturing and Ankur Seeds marketing of enzymes for Business: Engaged in research, different industries processing and developing CEO: Chandrakant L Rathi (MD) hybrid and Bt seeds Biotech Revenue: Rs 69.30 crore CEO: MG Shembekar (MD) Start-up Year: 1958Biotech Revenue: Rs 69.50 crore Address: 5th Floor A Wing Sun Start-up Year: 1976 Magnetica, Galaxy Accolade,Address: 27, New Cotton Market Next to LIC Building, Service Layout, Nagpur - 440 018 Road, Louis Wadi, Near Teen Hath Naka,Thane-(w)400604
Market Forecast Favorable Climate• According to the “India in • Indian Copyright Act, 1957 Business”, Ministry of External • The Patent Act, 1970 Affairs, Govt of India the forecast • Indian Patents and Design Act, for 2015 is that the Indian biotech 1972 industry would have an annual • The Trademarks Act, 1999 revenues in excess of US$13 billion • Biotechnology Patent Facilitating Cell (BPFC)• According to Global Industry Analysis-The Biotechnology • Foundation of Biotechnology industry in India to reach $11.6 Awareness and Education (FBAE) billion by 2017 • National Research Development Corporation (NRDC)
A particular slide catching your eye?
Clipping is a handy way to collect important slides you want to go back to later.